Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022

Business Wire July 25, 2022

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

Business Wire July 22, 2022

Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance

Business Wire July 14, 2022

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $250,000 to Contact the Firm

PR Newswire June 14, 2022

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $250,000 to Contact the Firm

Newsfile June 14, 2022

AUPH ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in the Class Action Filed on Behalf of Aurinia Pharmaceuticals Inc. Shareholders

PR Newswire June 14, 2022

Aurinia Pharmaceuticals Inc. Class Action: Levi & Korsinsky Reminds Aurinia Pharmaceuticals Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 14, 2022 - AUPH

Newsfile June 13, 2022

Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Last Day to Actively Participate

Business Wire June 13, 2022

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 13, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Aurinia Pharmaceuticals Inc. Investors of a Lead Plaintiff Deadline of June 14, 2022

PR Newswire June 13, 2022

AUPH FINAL DEADLINE JUNE 14: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - AUPH

Newsfile June 12, 2022

AURINIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Business Wire June 11, 2022

AUPH FINAL DEADLINE ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 14 Deadline in Securities Class Action - AUPH

PR Newswire June 10, 2022

TUESDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 10, 2022

AUPH SHAREHOLDER ALERT: Jakubowitz Law Reminds Aurinia Pharmaceuticals Inc. Shareholders of a Lead Plaintiff Deadline of June 14, 2022

PR Newswire June 10, 2022

DEADLINE NEXT TUESDAY: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPH

Newsfile June 9, 2022

TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 9, 2022

AUPH LAWSUIT ALERT: Levi & Korsinsky Notifies Aurinia Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire June 9, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aurinia Pharmaceuticals Inc., of Class Action Lawsuit and Upcoming Deadline - AUPH

PR Newswire June 8, 2022

Aurinia Pharmaceuticals Inc. Class Action: Levi & Korsinsky Reminds Aurinia Pharmaceuticals Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 14, 2022 - AUPH

Newsfile June 8, 2022